|
1
|
Fishman DA, Roberts KB, Chambers JT,
Kohorn EI, Schwartz PE and Chambers SK: Radiation therapy as
exclusive treatment for medically inoperable patients with stage I
and II endometrioid carcinoma with endometrium. Gynecol Oncol.
61:189–196. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coon D, Beriwal S, Heron DE, Kelley JL,
Edwards RP, Sukumvanich P, Zorn KK and Krivak TC: High-dose-rate
Rotte ‘Y’ applicator brachytherapy for definitive treatment of
medically inoperable endometrial cancer: 10-year results. Int J
Radiat Oncol Biol Phys. 71:779–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niazi TM, Souhami L, Portelance L, Bahoric
B, Gilbert L and Stanimir G: Long-term results of high-dose-rate
brachytherapy in the primary treatment of medically inoperable
stage I–II endometrial carcinoma. Int J Radiat Oncol Biol Phys.
63:1108–1113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lutz ST, Chow EL, Hartsell WF and Konski
AA: A review of hypofractionated palliative radiotherapy. Cancer.
109:1462–1470. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gill BS, Chapman BV, Hansen KJ,
Sukumvanich P and Beriwal S: Primary radiotherapy for nonsurgically
managed Stage I endometrial cancer: Utilization and impact of
brachytherapy. Brachytherapy. 14:373–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caravatta L, Padula GD, Macchia G,
Ferrandina G, Bonomo P, Deodato F, Massaccesi M, Mignogna S,
Tambaro R, Rossi M, et al: Short-course accelerated radiotherapy in
palliative treatment of advanced pelvic malignancies: A phase I
study. Int J Radiat Oncol Biol Phys. 83:e627–e631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim DH, Lee JH, Ki YK, Nam JH, Kim WT,
Jeon HS, Park D and Kim DW: Short-course palliative radiotherapy
for uterine cervical cancer. Radiat Oncol J. 31:216–21. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spanos WJ Jr, Perez CA, Marcus S, Poulter
CA, Doggett RL, Steinfeld AD and Grigsby PW: Effect of rest
interval on tumor and normal tissue response-a report of phase III
study of accelerated split course palliative radiation for advanced
pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys.
25:399–403. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan J, Milosevic M, Fyles A, Manchul L,
Kelly V and Levin W: A hypofractionated radiotherapy regimen
(0-7-21) for advanced gynaecological cancer patients. Clin Oncol (R
Coll Radiol). 23:476–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai CH and Huang HJ: The role of hormones
for the treatment of endometrial hyperplasia and endometrial
cancer. Curr Opin Obstet Gynecol. 18:29–34. 2006.PubMed/NCBI
|
|
11
|
Leslie KK, Thiel KW and Yang S:
Endometrial cancer: Potential treatment and prevention with
progestin-containing intrauterine devices. Obstet Gynecol.
119:419–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mountzios G, Pectasides D, Bournakis E,
Pectasides E, Bozas G, Dimopoulos MA and Papadimitriou CA:
Developments in the systemic treatment of endometrial cancer. Crit
Rev Oncol Hematol. 79:278–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dhar KK, NeedhiRajan T, Koslowski M and
Woolas RP: Is levonorgestrel intrauterine system effective for
treatment of early endometrial cancer? Report of four cases and
review of the literature. Gynecol Oncol. 97:924–927. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giannopoulos T, Butler-Manuel S and Tailor
A: Levonorgestrel-releasing intrauterine system (LNG-IUS) as a
therapy for endometrial carcinoma. Gynecol Oncol. 95:762–764. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montz FJ, Bristow RE, Bovicelli A,
Tomacruz R and Kurman RJ: Intrauterine progesterone treatment of
early endometrial cancer. Am J Obstet Gynecol. 186:651–657. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toivonen J and Luukkainen T:
Progestin-releasing intrauterine devices. Curr Ther Endocrinol
Metab. 6:281–285. 1997.PubMed/NCBI
|
|
17
|
Gallos ID, Shehmar M, Thangaratinam S,
Papapostolou TK, Coomarasamy A and Gupta JK: Oral progestogens vs.
levonorgestrel-releasing intrauterine system for endometrial
hyperplasia: A systematic review and meta-analysis. Am J Obstet
Gynecol. 203(547): e1–e10. 2010.PubMed/NCBI
|
|
18
|
Gallos ID, Krishan P, Shehmar M, Ganesan R
and Gupta JK: LNG-IUS versus oral progestogen treatment for
endometrial hyperplasia: A long-term comparative cohort study. Hum
Reprod. 28:2966–2971. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guttinger A and Critchley H: Endometrial
effects of intrauterine levonorgestrel. Contraception. 75(6 Suppl):
S93–S98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luukkainen T, Lähteenmäki P and Toivonen
J: Levonorgestrel-releasing intrauterine device. Ann Med. 22:85–90.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
André Wambersie and Torsten Landberg: ICRU
report 62: Prescribing, recording and reporting photon beam therapy
(Supplement to ICRU Report 50). ICRU. Bethesda, MD: 1999.
|
|
22
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaplan EL and Meier P: Non-parametric
estimation from incomplete observations. J Am Statist Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
24
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, national cancer
institute of the united states, national cancer institute of
canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mishra SK, Laskar S, Muckaden MA, Mohindra
P, Shrivastava SK and Dinshaw KA: Monthly palliative pelvic
radiotherapy in advanced carcinoma of uterine cervix. J Cancer Res
Ther. 1:208–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramirez PT, Frumovitz M, Bodurka DC, Sun
CC and Levenback C: Hormonal therapy for the management of grade 1
endometrial adenocarcinoma: A literature review. Gynecol Oncol.
95:133–138. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carcangiu ML, Chambers JT, Voynick IM,
Pirro M and Schwartz PE: Immunohistochemical evaluation of estrogen
and progesterone receptor content in 183 patients with endometrial
carcinoma. Part I: Clinical and histologic correlations. Am J Clin
Pathol. 94:247–254. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mhawech-Fauceglia P, Yan L, Liu S and
Pejovic T:
ER+/PR+/TFF3+/IMP3−
immunoprofile distinguishes endometrioid from serous and clear cell
carcinomas of the endometrium: A study of 401 cases.
Histopathology. 62:976–985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bokhman JV, Chepick OF, Volkova AT and
Vishnevsky AS: Can primary endometrial carcinoma stage I be cured
without surgery and radiation therapy? Gynecol Oncol. 20:139–155.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gotlieb WH, Beiner ME, Shalmon B, Korach
Y, Segal Y, Zmira N, Koupolovic J and Ben-Baruch G: Outcome of
fertility-sparing treatment with progestins in young patients with
endometrial cancer. Obstet Gynecol. 102:718–725. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hahn HS, Yoon SG, Hong JS, Hong SR, Park
SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, et al: Conservative
treatment with progestin and pregnancy outcomes in endometrial
cancer. Int J Gynecol Cancer. 19:1068–1073. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaku T, Yoshikawa H, Tsuda H, Sakamoto A,
Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S, et
al: Conservative therapy for adenocarcinoma and atypical
endometrial hyperplasia of the endometrium in young women: Central
pathologic review and treatment outcome. Cancer Lett. 167:39–48.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koskas M, Yazbeck C, Walker F, Clouqueur
E, Agostini A, Ruat S, Lucot JP, Lambaudie E, Luton D and Madelenat
P: Fertility-sparing management of grade 2 and 3 endometrial
adenocarcinomas. Anticancer Res. 31:3047–3049. 2011.PubMed/NCBI
|
